<DOC>
	<DOCNO>NCT02113735</DOCNO>
	<brief_summary>This study perform evaluate potential efficacy safety Acthar treatment moderate-severe Acute Respiratory Distress Syndrome ( ARDS ) . Approximately 210 subject randomize 1 6 possible treatment group 3:2:3:2:3:2 ratio . Study medication ( SM ) administer via subcutaneous ( SC ) injection 4 week use blind gradually taper regimen , subject follow 60 day post-randomization .</brief_summary>
	<brief_title>Safety Efficacy Study Acthar Subjects With ARDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Patients ≥ 18 year . 2 . ARDS define : PaO2 /FiO2 ≤ 200 mmHg PEEP ≥ 5cm H2O . Bilateral opacities chest radiography explain atelectasis , effusion , nodule , preexist disease . Requirement positive pressure ventilation via endotracheal tube . Respiratory failure fully explain cardiac failure fluid overload . If identifiable risk factor ARDS identify , leave atrial hypertension must exclude objective measure ( e.g . transthoracic echocardiogram ) . Criteria 2a , 2b , 2c must occur within 24 hr period . 3 . Enrollment 24 hour 10 day ARDS criterion meet . 1 . Subject unwilling receive intolerant SC injection . 2 . Subject , surrogate , physician commit full supportive care . A `` Do Not Resuscitate '' ( DNR ) order alone without limitation care require study exclusion . 3 . Moribund subject death perceive imminent . For purpose study , moribund define requirement ≥ 2 high dose vasopressor AND acute organ failure ≥ 3 organ ≥ 24 hour prior study entry . 4 . Home mechanical ventilation ( noninvasive ventilation via tracheotomy ) except continuous positive airway pressure bilevel positive airway pressure ( CPAP/BIPAP ) use solely sleepdisordered breathe prior onset ARDS . 5 . Known contraindication Acthar per package insert Section 4 ( Appendix C ) : scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction . 6 . Gastrointestinal/Hepatic : History chronic active hepatitis , active Hepatitis B acute chronic Hepatitis C infection , OR moderatesevere chronic liver disease define ChildPugh Score &gt; 11 ( http : //gihep.com/calculators/hepatology/childpughscore/ ) , OR evidence hemodynamically significant active gastrointestinal ( GI ) bleeding . 7 . Any subject sign symptom concern active infection treat &gt; 48 hour prior randomization either empiric broadspectrum pathogendirected antimicrobial therapy . 8 . Immune System : Known immunecompromised status , include limited individual undergone organ transplantation know positive human immunodeficiency virus ( HIV ) . 9 . Burns &gt; 20 % total body surface area , burn injury accompany smoke inhalational injury . 10 . Major surgery within 48 hour randomization , OR evidence currently active bleed postoperatively , OR plan major surgery study period . 11 . Administration investigational drug participation interventional clinical research study ARDS within 30 day plan randomization 60 day study duration . 12 . Presence clinically significant disease disorder ( include list Appendix C package insert Section 5 [ Warnings Precautions ] ) , opinion Investigator ( nature inadequately control ) , might put subject risk due participation study , may influence result study subject 's ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ARDS</keyword>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Acthar</keyword>
	<keyword>ACTH</keyword>
	<keyword>H.P . Acthar Gel</keyword>
</DOC>